Lower prolactin levels are associated with histological severity of metabolic dysfunction-associated steatotic liver disease Authors: Huayang Ma, Pengzi Zhang, Da Fang, Yan Bi, Tianwei Gu Published: 2026 ABSTRACT PurposeProlactin, a hormone synthesized by pituitary, was associated with metabolic dysfunction-associated steatotic liver disease (MASLD). Metabolic dysfunction-associated steatohepatitis (MASH) is the more severe manifestation of MASLD. We investigated whether prolactin levels correlate with the severity of MASLD and its histological features.MethodsParticipants were categorized into non-MASLD, non-MASH, and MASH based on histopathological criteria. Baseline clinical and biological characteristics were compared according to MASLD status. Participants were further classified into tertiles based on prolactin levels, and binary regression analysis was used to assess the association between prolactin levels and MASLD/MASH. Subgroup analyses were performed according to sex, BMI, and glycemic status. Mediation analysis was performed to explore the relationship between prolactin and hepatic pathological features.ResultsThis study enrolled 742 subjects (median age 31.0 years, median BMI 38.06 kg/m2, 64.29% females), of whom 67 had non-MASLD, 190 had non-MASH, and 485 had MASH. Serum prolactin levels were significantly lower in MASH group (median: 9.38 µg/L; IQR: 7.37–11.90) compared with non-MASLD group (median: 11.65 µg/L; IQR: 9.18–15.86) and non-MASH group (median: 9.91 µg/L; IQR: 8.08–13.00). After adjusting for potential confounders, subjects in the lowest prolactin tertile had significantly higher odds of MASLD (OR: 3.117; 95% CI: 1.253–7.757) and MASH (OR: 1.676; 95% CI: 1.110–2.530) compared with those in the highest tertile. Subgroup analyses suggested that this association was consistent across BMI and glycemic subgroups but restricted to females. Furthermore, prolactin levels were inversely correlated with steatosis score (rs = -0.207, p < 0.001) and inflammation score (rs = -0.148, p < 0.001), but not with ballooning score (rs = -0.015, p = 0.682) or fibrosis score (rs = 0.031, p = 0.410). The effects of prolactin on NAFLD activity score, steatosis score, and inflammatory score were mediated by HOMA-IR, with mediation proportions of 17.03%, 16.08% and 17.32%, respectively.ConclusionLower prolactin levels are associated with histological severity of MASLD, particularly in terms of hepatic steatosis and inflammation.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12902-026-02344-5. Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is now defined as excess lipid deposition in liver accompanied by at least one cardiometabolic risk factor [1]. Currently, it is the most prevalent chronic liver disease, affecting 30–40% of adults [2]. MASLD encompasses a spectrum of disorders, including metabolic dysfunction-associated steatotic liver (MASL), metabolic dysfunction-associated steatohepatitis (MASH) (formerly nonalcoholic steatohepatitis, NASH), cirrhosis, and hepatocellular carcinoma [1]. A proportion of patients with MASL may evolve into MASH, in which hepatic lipid accumulation, hepatocyte injury and lobular inflammation occur [3]. Compared with MASL patients, those with MASH are at greater risk of metabolic disorders, cardiovascular disease, cirrhosis, hepatocellular carcinoma, and liver-specific or overall mortality [4–6]. Patients at high risk for MASH may benefit from early detection and treatment. Among the various pathogenic mechanisms, insulin resistance is an important factor contributing to the development and the progression of MASLD [7]. However, the factors that may promote the development of MASH in obese patients remain insufficiently investigated. It is imperative to identify risk factors and pathological mechanisms of MASH. Prolactin (PRL) is a polypeptide hormone produced and secreted by the pituitary gland [8]. Beyond its role in lactation, PRL exerts endocrine and metabolic functions [9]. It has been demonstrated that lower PRL levels considerably increased the risk of insulin resistance and metabolic diseases [10, 11]. Several studies have reported that PRL levels were significantly lower in MASLD patients than in non-MASLD populations [12–14]. However, those investigations primarily used B-ultrasound to diagnose fatty liver. To verify the connection between PRL and MASLD, studies with larger liver biopsy sample sizes are required. Moreover, the relationship between PRL and the severity of MASLD and its histological features has not yet been investigated. Therefore, this study explored the association between plasma PRL levels and the presence and severity of MASLD in patients undergoing liver biopsy. Patients and methods Participants in the study We enrolled 996 participants aged 18 to 80 years who underwent liver biopsy at the Endocrinology Department of Drum Tower Hospital affiliated with Nanjing University Medical School, from January 2016 to October 2022. Exclusion criteria were as follow: alcohol consumption exceeding 20 g per day for women or 30 g per day for men (n = 53); history of chronic liver disease, such as autoimmune hepatitis, biliary obstruction and so on (n = 14); hyperprolactinemia (n = 6); hyperthyroidism or hypothyroidism (n = 82); use of systematic corticosteroids (n = 3); pituitary disease (15); severe heart, lung, or kidney disease (n = 13); malignant tumor (n = 15); menopause; pregnancy; use of hepatotoxic medications, steatogenic medication, lipid-lowering agents, or medications known to affect prolactin levels (n = 37); and those with missing data on prolactin (n = 16). Finally, a total of 742 subjects were included in the final analysis. Histological assessment and definition of non-MASH and MASH Liver histology was assessed independently by two experienced pathologists blinded to clinical data [15]. The proportion of hepatocytes with fat droplets was used to determine steatosis scores: S0 (< 5%), S1 (5–33%), S2 (33–66%) and S3 (> 66%). The scores for hepatocyte ballooning were defined as follows: 0 (none), 1 (few balloon cells), and 2 (prominent ballooning). Based on the number of foci, lobular inflammation (LI) was classified as LI0 (none), LI1 (< 2 foci), LI2 (2–4 foci), and LI3 (> 4 foci). The scores for fibrosis were defined as follows: F0 (none), F1 (perisinusoidal or periportal fibrosis), F2 (perisinusoidal and portal/periportal fibrosis), F3 (bridging fibrosis), and F4 (cirrhosis). The NAFLD activity score (NAS) was calculated by summing the scores of steatosis, ballooning and lobular inflammation. Macrovesicular steatosis affecting at least 5% of hepatocytes was characterized as MASLD. In patients with MASLD, those with hepatocyte ballooning ≥ 1 and lobular inflammation ≥1 were classified as MASH, others were non-MASH. Subgroup analysis Subgroup analyses were performed according to sex, BMI (< 35 kg/m2 vs. ≥35 kg/m2), and glycemic status, given their potential relevance to both circulating PRL levels and MASLD/MASH severity [16–20]. Glycemic status was categorized as normoglycemia or prediabetes/diabetes according to the American Diabetes Association criteria [21]. Anthropometric and biochemical measurements Electronic medical records were retrospectively reviewed for anthropometric and biochemical data. Anthropometric measurements involved height, weight, and blood pressure. BMI was computed as weight (kg) divided by height squared (m2). Participants were instructed to fast overnight before biochemical measurements. Blood samples were obtained from the antecubital vein after fasting. The hexokinase technique was used to measure the plasma glucose levels (TBA-200FR, Tokyo, Japan). An electrochemiluminescent immunoassay (Roche) was used to measure fasting insulin (FINS). Haemoglobin A1c (HbA1c) was determined by HPLC (HLC-73G8, Tosoh, Japan). An autoanalyzer (Abbott Laboratories, USA) was used to measure aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AKP), γ - glutamyl transferase (GGT), triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C). An automated chemiluminescent immunoassay (Siemens Immulite 2000, Siemens Healthcare Diagnostic Products Ltd, UK) was used to measure prolactin (PRL). Insulin resistance was calculated by the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) [22]. \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\eqalign{ {\rm{HOMA}} - {\rm{IR}} = & {\rm{fasting\,insulin}} \cr & {\rm{(FINS,\mu IU/mL)}} \cr & \times {\rm{fasting\,blood\,glucose}} \cr & {\rm{}}\left( {{\rm{FBG}},{\rm{mmol}}/{\rm{L}}} \right) \div 22.5 \cr}$$\end{document} Statistical analysis Categorical variables were presented as frequencies and percentages, and continuous variables as mean ± standard deviation or median with interquartile range, as appropriate. Baseline clinical characteristics were compared by MASLD status. For comparisons between two groups with non-normally distributed data, the Mann-Whitney U test was utilized. For comparisons among three or more groups with non-normally distributed data, the Kruskal-Wallis test was used. For normally distributed data, the independent t-test was used for two group comparisons, and analysis of variance (ANOVA) for three or more groups. Differences in categorical variables were examined using the chi-square test. Binary logistic regression analysis was used to determine the associations between PRL and MASLD/MASH. Spearman correlation analysis was used to evaluate the associations between PRL levels and anthropometric, biochemical, and histological parameters. Statistical significance was defined as a two-sided p value < 0.05. SPSS version 26.0 (IBM Inc., Armonk, NY, USA) was utilized for statistical analysis. Mediation analysis was performed using the PROCESS SPSS macro to determine how PRL levels influenced the liver histopathologic characteristics through HOMA-IR, using 5,000 bootstrap samples to generate bias-corrected 95% confidence intervals. Results Characteristics of participants A total of 742 participants who underwent liver biopsy were included in the study. The median age was 31.0 (26.0, 37.0) years, median BMI was 38.06 (34.04, 42.48) kg/m2, and 64.29% were females. Among them, 67 (9.03%) participants were non-MASLD, 190 (25.61%) were non-MASH, and 485 (65.36%) were MASH. Histological evaluation of liver biopsies showed that the prevalence of hepatic steatosis, ballooning, inflammation, and fibrosis was 675 (90.97%), 665 (89.62%), 566 (76.28%), and 636 (85.71%), respectively (Supplementary table S1). The MASLD patients had higher BMI, SBP, DBP, FBG, FINS, HOMA-IR, HbA1c, ALT, AST, AKP, GGT, TG, TC, LDL-C, and lower HDL-C levels (all p < 0.05) compared with non-MASLD group (Supplementary table S2). Among MASLD patients, those with MASH had higher BMI, FBG, FINS, HOMA-IR, ALT, AST, GGT, and TC levels (all p < 0.05) than non-MASH patients (Table 1). Table 1Demographic and clinical characteristics of all participantsCharacteristicOverall(n = 742)Non-MASLD(n = 67)Non-MASH(n = 190)MASH(n = 485)Overallp-valueNon-MASLD vs. Non-MASH p-valueNon-MASLD vs. MASH p-valueNon-MASH vs. MASH p-valueAge (years)31.0 (26.0, 37.0)31.0 (23.0, 38.0)30.0 (25.0, 37.0)32.0 (27.0, 37.0)0.197---Gender (Male,%)265 (35.71)12 (17.91)71 (37.37)182 (37.53)0.006---Diabetes(%)239 (32.21)6 (8.96)58 (30.53)175 (36.08)< 0.001---Smoking(%)118 (15.90)6 (8.86)27 (14.21)85 (17.53)0.151---Drinking(%)32 (4.31)0 (0)7 (3.68)25 (5.15)0.128---BMI (kg/m2)38.06 (34.04, 42.48)34.29 (32.02, 38.09)37.22 (33.66, 41.44)38.96 (34.94, 43.56)< 0.0010.009< 0.0010.009SBP (mmHg)140 (129, 152)135 (122, 147)139 (129, 150)141 (129, 153)0.0100.1870.0100.524DBP (mmHg)89 (81, 100)85 (78, 95)88 (80, 98)90 (82, 101)0.0150.2540.0170.520FBG (mmol/L)5.38 (4.81, 6.62)4.80 (4.48, 5.23)5.22 (4.80, 6.08)5.59 (4.92, 7.02)< 0.001< 0.001< 0.0010.005FINS (µIU/ml)25.86 (17.40, 35.89)14.85 (9.30, 19.62)24.70 (16.53, 35.20)28.75 (20.50, 37.35)< 0.001< 0.001< 0.0010.007HOMA-IR6.53 (4.43, 9.80)3.14 (1.96, 4.23)6.17 (4.14, 9.13)7.31 (5.19, 10.53)< 0.001< 0.001< 0.0010.001HbA1c (%)5.80 (5.40, 6.70)5.30 (5.10, 5.70)5.80 (5.50, 6.40)5.90 (5.50, 7.10)< 0.001< 0.001< 0.0010.383ALT (U/L)42.35 (25.10, 74.50)18.20 (14.40, 23.20)36.85 (23.78, 60.63)50.10 (30.60, 82.50)< 0.001< 0.001< 0.001< 0.001AST (U/L)27.35 (18.78, 41.80)16.50 (14.90, 22.80)24.55 (17.15, 36.63)31.70 (21.20, 46.70)< 0.001< 0.001< 0.001< 0.001AKP (U/L)68.70 (57.93, 82.05)62.70 (53.60, 75.10)67.80 (56.10, 80.50)69.70 (59.05, 83.35)0.0140.1300.0120.913GGT (U/L)40.90 (27.58, 64.80)24.60 (18.80, 37.60)37.60 (25.70, 60.65)46.70 (31.10, 70.35)< 0.001< 0.001< 0.0010.007TG (mmol/L)1.60 (1.20, 2.26)1.26 (0.96, 1.66)1.55 (1.20, 2.31)1.68 (1.25, 2.31)< 0.001< 0.001< 0.0010.816TC (mmol/L)4.74 (4.24, 5.37)4.48 (3.92, 5.07)4.68 (4.23, 5.14)4.85 (4.30, 5.48)0.0010.6510.0070.027HDL-C (mmol/L)1.00 (0.87, 1.18)1.08 (0.91, 1.29)0.99 (0.87, 1.19)0.99 (0.86, 1.16)0.0150.0750.011> 0.999LDL-C (mmol/L)2.87 (2.37, 3.35)2.64 (2.24,3.23)2.87 (2.44, 3.27)2.92 (2.39, 3.40)0.082---PRL (µg/L)9.71 (7.63, 12.41)11.65 (9.18, 15.86)9.91 (8.08, 13.00)9.38 (7.37, 11.90)< 0.0010.004< 0.0010.048Data are expressed as median (interquartile range) for continuous variables or counts (%) for categorical variables. Statistical significance was defined as p < 0.05MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AKP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PRL, prolactin Table 1Demographic and clinical characteristics of all participantsCharacteristicOverall(n = 742)Non-MASLD(n = 67)Non-MASH(n = 190)MASH(n = 485)Overallp-valueNon-MASLD vs. Non-MASH p-valueNon-MASLD vs. MASH p-valueNon-MASH vs. MASH p-valueAge (years)31.0 (26.0, 37.0)31.0 (23.0, 38.0)30.0 (25.0, 37.0)32.0 (27.0, 37.0)0.197---Gender (Male,%)265 (35.71)12 (17.91)71 (37.37)182 (37.53)0.006---Diabetes(%)239 (32.21)6 (8.96)58 (30.53)175 (36.08)< 0.001---Smoking(%)118 (15.90)6 (8.86)27 (14.21)85 (17.53)0.151---Drinking(%)32 (4.31)0 (0)7 (3.68)25 (5.15)0.128---BMI (kg/m2)38.06 (34.04, 42.48)34.29 (32.02, 38.09)37.22 (33.66, 41.44)38.96 (34.94, 43.56)< 0.0010.009< 0.0010.009SBP (mmHg)140 (129, 152)135 (122, 147)139 (129, 150)141 (129, 153)0.0100.1870.0100.524DBP (mmHg)89 (81, 100)85 (78, 95)88 (80, 98)90 (82, 101)0.0150.2540.0170.520FBG (mmol/L)5.38 (4.81, 6.62)4.80 (4.48, 5.23)5.22 (4.80, 6.08)5.59 (4.92, 7.02)< 0.001< 0.001< 0.0010.005FINS (µIU/ml)25.86 (17.40, 35.89)14.85 (9.30, 19.62)24.70 (16.53, 35.20)28.75 (20.50, 37.35)< 0.001< 0.001< 0.0010.007HOMA-IR6.53 (4.43, 9.80)3.14 (1.96, 4.23)6.17 (4.14, 9.13)7.31 (5.19, 10.53)< 0.001< 0.001< 0.0010.001HbA1c (%)5.80 (5.40, 6.70)5.30 (5.10, 5.70)5.80 (5.50, 6.40)5.90 (5.50, 7.10)< 0.001< 0.001< 0.0010.383ALT (U/L)42.35 (25.10, 74.50)18.20 (14.40, 23.20)36.85 (23.78, 60.63)50.10 (30.60, 82.50)< 0.001< 0.001< 0.001< 0.001AST (U/L)27.35 (18.78, 41.80)16.50 (14.90, 22.80)24.55 (17.15, 36.63)31.70 (21.20, 46.70)< 0.001< 0.001< 0.001< 0.001AKP (U/L)68.70 (57.93, 82.05)62.70 (53.60, 75.10)67.80 (56.10, 80.50)69.70 (59.05, 83.35)0.0140.1300.0120.913GGT (U/L)40.90 (27.58, 64.80)24.60 (18.80, 37.60)37.60 (25.70, 60.65)46.70 (31.10, 70.35)< 0.001< 0.001< 0.0010.007TG (mmol/L)1.60 (1.20, 2.26)1.26 (0.96, 1.66)1.55 (1.20, 2.31)1.68 (1.25, 2.31)< 0.001< 0.001< 0.0010.816TC (mmol/L)4.74 (4.24, 5.37)4.48 (3.92, 5.07)4.68 (4.23, 5.14)4.85 (4.30, 5.48)0.0010.6510.0070.027HDL-C (mmol/L)1.00 (0.87, 1.18)1.08 (0.91, 1.29)0.99 (0.87, 1.19)0.99 (0.86, 1.16)0.0150.0750.011> 0.999LDL-C (mmol/L)2.87 (2.37, 3.35)2.64 (2.24,3.23)2.87 (2.44, 3.27)2.92 (2.39, 3.40)0.082---PRL (µg/L)9.71 (7.63, 12.41)11.65 (9.18, 15.86)9.91 (8.08, 13.00)9.38 (7.37, 11.90)< 0.0010.004< 0.0010.048Data are expressed as median (interquartile range) for continuous variables or counts (%) for categorical variables. Statistical significance was defined as p < 0.05MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AKP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PRL, prolactin Demographic and clinical characteristics of all participants Data are expressed as median (interquartile range) for continuous variables or counts (%) for categorical variables. Statistical significance was defined as p < 0.05 MASLD, metabolic dysfunction-associated steatotic liver disease; MASH, metabolic dysfunction-associated steatohepatitis; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AKP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PRL, prolactin Lower PRL levels were associated with biopsy-proven MASLD PRL levels were significantly lower in MASLD group (9.50 [7.49, 12.17] µg/L) than in non-MASLD group (11.65 [9.18, 15.86] µg/L, p < 0.001) (Supplementary table S2). All subjects were classified into tertiles according to PRL levels (tertile ranges from T1 to T3: <8.38, 8.38–11.44, > 11.44 µg/L, Table 2). Binary regression analysis showed that the lowest serum PRL tertile was associated with higher odds of MASLD compared with the highest PRL tertile (OR: 4.512 [2.124, 9.586], p < 0.001). These findings remained consistent even after adjusting for gender, BMI, SBP, DBP (Table 3, adjusted model 2); after further adjustment for HOMA-IR, HbA1c (Table 3, adjusted model 3); and after additional adjustment for ALT, AST, AKP, GGT, TG, TC, and HDL-C (Table 3, adjusted model 4). Sex-stratified analyses showed that the association between PRL tertiles and MASLD remained significant in women but not in men (Supplementary Tables S4-S7). In addition, subgroup analyses were performed according to sex, BMI (< 35 kg/m2 vs. ≥35 kg/m2), and glycemic status (normoglycemia vs. prediabetes/diabetes). Low PRL levels were independently associated with an increased risk of MASLD across BMI and glycemic status subgroups, although this association was not significant in males (Fig. 1). No significant interactions were observed between PRL and sex, BMI, or glycemic status. We further tested the association between serum PRL and the degree of liver steatosis. Serum PRL levels decreased gradually with increasing severity of hepatic steatosis (Fig. 2). Spearman analysis revealed that PRL concentrations were inversely correlated with the degree of hepatic steatosis (rs = -0.207, p < 0.001) (Supplementary table S3). Besides, spearman analysis showed negative correlations between PRL and FBG, FINS, HOMA-IR, HbA1c, ALT, AST, GGT, and TG (Supplementary table S3). Table 2Demographic and clinical characteristics of participants according to PRL levelsCharacteristicProlactin levels (µg/L)p-valueT1 (n = 247)(< 8.38)T2 (n = 248)(8.38–11.44)T3 (n = 247)(> 11.44)Age (years)32.0 (27.0, 38.0)31.0 (26.0, 35.8)31.0 (26.0, 37.0)0.120BMI (kg/m2)38.28 (34.22, 42.45)38.55 (34.05, 43.91)37.20 (33.98, 41.64)0.083SBP (mmHg)139 (128, 150)143 (129, 156)139 (129, 150)0.045DBP (mmHg)88 (80, 97)94 (83, 102)87 (81, 98)< 0.001FBG (mmol/L)5.58 (4.92, 7.21)5.37 (4.81, 6.65)5.23 (4.77, 6.06)< 0.001FINS (µIU/ml)26.00 (17.30, 36.30)28.80 (19.90, 38.18)23.79 (16.39, 32.40)0.004HOMA-IR7.21 (4.70, 10.39)6.89 (4.62, 10.06)5.87 (3.90, 8.67)< 0.001HbA1c (%)6.00 (5.50, 7.45)5.80 (5.50, 6.60)5.70 (5.30, 6.30)< 0.001ALT (U/L)47.20 (29.50, 74.00)46.15 (26.63, 84.80)35.10 (21.10, 58.30)< 0.001AST (U/L)30.20 (20.40, 44.30)29.05 (18.83, 47.68)25.10 (17.30, 34.10)< 0.001AKP (U/L)69.00 (56.50, 83.10)69.55 (58.63, 82.90)67.60 (56.60, 80.00)0.361GGT (U/L)47.80 (32.10, 68.30)43.10 (28.00, 69.98)35.50 (23.60, 52.00)< 0.001TG (mmol/L)1.80 (1.31, 2.39)1.59 (1.20, 2.28)1.49 (1.08, 2.06)< 0.001TC (mmol/L)4.76 (4.25, 5.40)4.72 (4.22, 5.31)4.77 (4.23, 5.43)0.753HDL-C (mmol/L)0.98 (0.86, 1.11)0.98 (0.85, 1.14)1.05 (0.88, 1.24)0.004LDL-C (mmol/L)2.90 (2.42, 3.35)2.86 (2.37, 3.35)2.84 (2.36, 3.34)0.921Data are expressed as median (interquartile range) for continuous variables. Statistical significance was defined as p < 0.05BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AKP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol Table 2Demographic and clinical characteristics of participants according to PRL levelsCharacteristicProlactin levels (µg/L)p-valueT1 (n = 247)(< 8.38)T2 (n = 248)(8.38–11.44)T3 (n = 247)(> 11.44)Age (years)32.0 (27.0, 38.0)31.0 (26.0, 35.8)31.0 (26.0, 37.0)0.120BMI (kg/m2)38.28 (34.22, 42.45)38.55 (34.05, 43.91)37.20 (33.98, 41.64)0.083SBP (mmHg)139 (128, 150)143 (129, 156)139 (129, 150)0.045DBP (mmHg)88 (80, 97)94 (83, 102)87 (81, 98)< 0.001FBG (mmol/L)5.58 (4.92, 7.21)5.37 (4.81, 6.65)5.23 (4.77, 6.06)< 0.001FINS (µIU/ml)26.00 (17.30, 36.30)28.80 (19.90, 38.18)23.79 (16.39, 32.40)0.004HOMA-IR7.21 (4.70, 10.39)6.89 (4.62, 10.06)5.87 (3.90, 8.67)< 0.001HbA1c (%)6.00 (5.50, 7.45)5.80 (5.50, 6.60)5.70 (5.30, 6.30)< 0.001ALT (U/L)47.20 (29.50, 74.00)46.15 (26.63, 84.80)35.10 (21.10, 58.30)< 0.001AST (U/L)30.20 (20.40, 44.30)29.05 (18.83, 47.68)25.10 (17.30, 34.10)< 0.001AKP (U/L)69.00 (56.50, 83.10)69.55 (58.63, 82.90)67.60 (56.60, 80.00)0.361GGT (U/L)47.80 (32.10, 68.30)43.10 (28.00, 69.98)35.50 (23.60, 52.00)< 0.001TG (mmol/L)1.80 (1.31, 2.39)1.59 (1.20, 2.28)1.49 (1.08, 2.06)< 0.001TC (mmol/L)4.76 (4.25, 5.40)4.72 (4.22, 5.31)4.77 (4.23, 5.43)0.753HDL-C (mmol/L)0.98 (0.86, 1.11)0.98 (0.85, 1.14)1.05 (0.88, 1.24)0.004LDL-C (mmol/L)2.90 (2.42, 3.35)2.86 (2.37, 3.35)2.84 (2.36, 3.34)0.921Data are expressed as median (interquartile range) for continuous variables. Statistical significance was defined as p < 0.05BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AKP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol Demographic and clinical characteristics of participants according to PRL levels Data are expressed as median (interquartile range) for continuous variables. Statistical significance was defined as p < 0.05 BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose; FINS, fasting insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HbA1c, hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AKP, alkaline phosphatase; GGT, gamma-glutamyl transferase; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol Table 3Multivariate analysis producing odds ratios (ORs) with 95% confidence intervals (CIs) for MASLDModel 1Model 2Model 3Model 4OR (95%CI) p OR (95%CI) p OR (95%CI) p OR (95%CI) p T14.512 (2.124, 9.586)< 0.0014.065 (1.887, 8.759)< 0.0013.334 (1.470, 7.560)0.0043.117 (1.253, 7.757)0.015T21.753 (0.999, 3.076)0.0511.433 (0.800, 2.566)0.2261.213 (0.648, 2.273)0.5461.116 (0.567, 2.196)0.751T31ref1ref1ref1refPer 1-SD increment0.873 (0.825, 0.923)< 0.0010.889 (0.839, 0.942)< 0.0010.885 (0.833, 0.941)< 0.0010.904 (0.839, 0.974)0.008Model 1: UnadjustedModel 2: Adjusted for Gender, BMI, SBP, DBPModel 3: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1cModel 4: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1c, ALT, AST, AKP, GGT, TG, TC, HDL-C Table 3Multivariate analysis producing odds ratios (ORs) with 95% confidence intervals (CIs) for MASLDModel 1Model 2Model 3Model 4OR (95%CI) p OR (95%CI) p OR (95%CI) p OR (95%CI) p T14.512 (2.124, 9.586)< 0.0014.065 (1.887, 8.759)< 0.0013.334 (1.470, 7.560)0.0043.117 (1.253, 7.757)0.015T21.753 (0.999, 3.076)0.0511.433 (0.800, 2.566)0.2261.213 (0.648, 2.273)0.5461.116 (0.567, 2.196)0.751T31ref1ref1ref1refPer 1-SD increment0.873 (0.825, 0.923)< 0.0010.889 (0.839, 0.942)< 0.0010.885 (0.833, 0.941)< 0.0010.904 (0.839, 0.974)0.008Model 1: UnadjustedModel 2: Adjusted for Gender, BMI, SBP, DBPModel 3: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1cModel 4: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1c, ALT, AST, AKP, GGT, TG, TC, HDL-C Multivariate analysis producing odds ratios (ORs) with 95% confidence intervals (CIs) for MASLD Model 1: Unadjusted Model 2: Adjusted for Gender, BMI, SBP, DBP Model 3: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1c Model 4: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1c, ALT, AST, AKP, GGT, TG, TC, HDL-C Fig. 1Multivariate analysis producing odds ratios (ORs) with 95% confidence intervals (CIs) for MASLD and MASH in different subgroups. Odds ratios (95% confidence intervals) of MASLD and MASH according to gender, BMI and glycemic status using logistic regression analysis Multivariate analysis producing odds ratios (ORs) with 95% confidence intervals (CIs) for MASLD and MASH in different subgroups. Odds ratios (95% confidence intervals) of MASLD and MASH according to gender, BMI and glycemic status using logistic regression analysis Fig. 2Associations between serum PRL levels and liver pathological features (n = 742, A-D). A: The associations between serum PRL levels and fat content. B: The associations between serum PRL levels and ballooning. C: The associations between serum PRL levels and lobular inflammation. D: The associations between serum PRL levels and fibrosis. Data are expressed as median (interquartile range). Level of significance: p < 0.05. Kruskal-Wallis analysis was used among three or more groups Associations between serum PRL levels and liver pathological features (n = 742, A-D). A: The associations between serum PRL levels and fat content. B: The associations between serum PRL levels and ballooning. C: The associations between serum PRL levels and lobular inflammation. D: The associations between serum PRL levels and fibrosis. Data are expressed as median (interquartile range). Level of significance: p < 0.05. Kruskal-Wallis analysis was used among three or more groups Lower PRL levels were associated with MASH, especially with lobular inflammation Then we explored the relationship between PRL levels and MASH. Serum PRL levels were significantly lower in MASH group (9.38 [7.37, 11.90] µg/L) than in non-MASLD group (11.65 [9.18, 15.86] µg/L, p < 0.001) and non-MASH group (9.91 [8.08, 13.00] µg/L, p = 0.048). Multiple regression analysis showed that after adjusting for gender, BMI, SBP, DBP, HOMA-IR, HbA1c, ALT, AST, GGT, TC, and HDL-C, patients in the lowest tertile had a significantly increased risk of MASH compared with those in the highest tertile (Table 4, adjusted model 4). The association between PRL and MASH remained consistent across BMI and glycemic status subgroups. When stratified by sex, a statistically significant association was observed only in females (Fig. 1). No significant interaction was found between PRL and sex, BMI, or glycemic status. In sex-specific tertile analysis, lower prolactin levels were related to MASH in females but not in males (Supplementary table S8-S9). We further analyzed the relationship between PRL levels and other histological features of MASLD. Serum PRL levels decreased gradually with increasing severity of lobular inflammation (Fig. 2). Spearman analysis revealed that PRL concentrations were negatively correlated with the degree of lobular inflammation (rs = -0.148, p < 0.001). However, PRL levels were not related to the ballooning score (rs = -0.015, p = 0.682) or fibrosis score (rs = 0.031, p = 0.410) (Supplementary table S3). Table 4Multivariate analysis producing odds ratios (ORs) with 95% confidence intervals (CIs) for MASHModel 1Model 2Model 3Model 4OR (95%CI) p OR (95%CI) p OR (95%CI) p OR (95%CI) p T11.979 (1.359, 2.882)< 0.0011.991 (1.350, 2.935)0.0011.753 (1.172, 2.620)0.0061.676 (1.110, 2.530)0.014T21.494 (1.038, 2.152)0.0311.380 (0.947, 2.012)0.0941.287 (0.873, 1.896)0.2031.220 (0.819, 1.817)0.327T31ref1ref1ref1refPer 1-SD increment0.917 (0.883, 0.953)< 0.0010.918 (0.882, 0.956)< 0.0010.929 (0.892, 0.968)< 0.0010.934 (0.895, 0.974)0.002Model 1: UnadjustedModel 2: Adjusted for Gender, BMI, SBP, DBPModel 3: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1cModel 4: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1c, ALT, AST, GGT, TC, HDL-C Table 4Multivariate analysis producing odds ratios (ORs) with 95% confidence intervals (CIs) for MASHModel 1Model 2Model 3Model 4OR (95%CI) p OR (95%CI) p OR (95%CI) p OR (95%CI) p T11.979 (1.359, 2.882)< 0.0011.991 (1.350, 2.935)0.0011.753 (1.172, 2.620)0.0061.676 (1.110, 2.530)0.014T21.494 (1.038, 2.152)0.0311.380 (0.947, 2.012)0.0941.287 (0.873, 1.896)0.2031.220 (0.819, 1.817)0.327T31ref1ref1ref1refPer 1-SD increment0.917 (0.883, 0.953)< 0.0010.918 (0.882, 0.956)< 0.0010.929 (0.892, 0.968)< 0.0010.934 (0.895, 0.974)0.002Model 1: UnadjustedModel 2: Adjusted for Gender, BMI, SBP, DBPModel 3: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1cModel 4: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1c, ALT, AST, GGT, TC, HDL-C Multivariate analysis producing odds ratios (ORs) with 95% confidence intervals (CIs) for MASH Model 1: Unadjusted Model 2: Adjusted for Gender, BMI, SBP, DBP Model 3: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1c Model 4: Adjusted for Gender, BMI, SBP, DBP, HOMA-IR, HbA1c, ALT, AST, GGT, TC, HDL-C The associations between PRL and histological severity of MASLD were mediated by HOMA-IR PRL levels were negatively correlated with HOMA-IR (rs = -0.133, p < 0.001) (Supplementary table S3). According to mediation analysis, 17.03% of the correlation between PRL and NAS score was mediated by HOMA-IR (b = -0.013 [95% bootstrap CI -0.021, -0.008]). The correlation between PRL and liver steatosis score was mediated by HOMA-IR with a mediation proportion of 16.08% (b = -0.009 [95% bootstrap CI -0.013, -0.005]). Furthermore, a significant mediation effect of HOMA-IR was observed in the association between PRL and inflammatory score with a mediation proportion of 17.32% (b = -0.004 [95% bootstrap CI -0.007, -0.002]) (Fig. 3). Fig. 3Mediation analysis of prolactin and liver pathological features. A: Mediation models included HOMA-IR as a mediator of the association between PRL and NAS score. B: Mediation models included HOMA-IR as a mediator of the association between PRL and steatosis score. C: Mediation models included HOMA-IR as a mediator of the association between PRL and inflammation score Mediation analysis of prolactin and liver pathological features. A: Mediation models included HOMA-IR as a mediator of the association between PRL and NAS score. B: Mediation models included HOMA-IR as a mediator of the association between PRL and steatosis score. C: Mediation models included HOMA-IR as a mediator of the association between PRL and inflammation score Discussion In this study, we investigated the relationship between prolactin levels and the severity of MASLD. In a large, pathologically confirmed cohort, we confirmed that PRL levels were significantly lower in patients with MASLD, consistent with previous findings. More importantly, we observed a stepwise decrease in PRL levels in patients with MASH. Lower PRL levels were mainly associated with hepatic steatosis and lobular inflammation, but not with hepatocyte ballooning or fibrosis. Prolactin is a polypeptide hormone, primarily generated and released by prolactin cells in the anterior lobe of the pituitary gland [23]. The most well-known physiological function of prolactin is to coordinate reproduction and lactation [23]. In addition, it also plays important roles in metabolism, immunity and stress regulation [24]. Recent studies have focused on the roles of prolactin in metabolic regulation [25], including glucolipid metabolism [20]. As an essential organ responsible for metabolic homeostasis, the liver has high expression of prolactin receptor (PRLR) [8, 24]. Our research group previously reported that lower serum PRL levels were associated with MASLD and that PRL improved hepatic lipid metabolism through CD36 pathway [14]. However, due to the limited sample size at that time, the association between PRL levels and the severity of MASLD was not further investigated. MASH represents an advanced stage of MASLD [26]. About 20% of MASH patients may progress to cirrhosis, raising the incidence of HCC and the need for liver transplantation [27]. In the present study, we found that PRL levels were lower in patients with MASLD and MASH. Given that sex, BMI, and glycemic status may influence both MASLD severity and circulating PRL levels, we performed subgroup analyses according to these variables. Hyperglycemia may reduce PRL levels by promoting lactotroph apoptosis, whereas obesity may increase PRL levels through adipose tissue expansion and enhanced aromatase-dependent estrogen production [18, 20, 28]. In addition, obesity and diabetes are important metabolic drivers of MASLD progression [19, 29]. In line with this, we observed consistent associations between lower PRL levels and increased odds of MASLD/MASH across BMI and glycemic status subgroups. However, this association was significant in women in both sex-stratified and sex-specific tertile analyses. The sex-specific association observed in our study may be partly explained by differences in hepatic PRL signaling. PRL acts primarily through its receptor, PRLR, and previous studies have reported higher hepatic PRLR expression in females than in males [30, 31]. Hepatic PRLR expression may be regulated by sex hormones, with estrogen promoting and androgen suppressing PRLR expression [32]. These findings raise the possibility that reduced hepatic PRLR expression in males may weaken the link between circulating PRL levels and MASLD/MASH. In addition, crosstalk between PRL and estrogen signaling may contribute to the stronger association observed in women. Estrogen receptors have been shown to enhance the transcriptional activity of PRL-activated STAT5b, which may amplify PRL-related metabolic effects in the liver [33], this may potentiate the regulatory function of prolactin in hepatic lipid metabolism. Consistently, Zhu et al. also reported that lower PRL levels were associated with MAFLD and liver fibrosis in women but not in men among patients with type 2 diabetes [34]. Further studies are needed to determine whether PRL contributes to MASLD/MASH progression in a sex-dependent manner. We further examined the association between PRL levels and the specific hepatic histological features of MASLD. PRL levels demonstrated a significant inverse correlation with both steatosis and inflammation scores. Our findings may be explained by the crucial role of PRL in regulating hepatic lipid metabolism and inflammation. Previous study has shown that PRL reduces hepatic lipid deposition by suppressing the expression of the fatty acid transporter CD36 and the lipogenic enzyme SCD1 [35]. Consequently, decreased PRL levels lead to upregulation of hepatic CD36 and SCD1, which enhances free fatty acid uptake and synthesis, resulting in more severe lipid accumulation and subsequent lipotoxicity. This cascade ultimately triggers hepatocyte injury and inflammation, driving progression to MASH [36]. Furthermore, higher PRL levels have been associated with lower concentrations of pro-inflammatory cytokines, including TNF-α in obese adults [37] and IL-6 in obese children [38], suggesting that PRL may ameliorate chronic inflammation. However, PRL levels were not associated with ballooning scores in our study. This finding is consistent with previous evidence suggesting that different biomarkers may reflect distinct histological dimensions of MASLD rather than all components uniformly. For example, Ajmera et al. reported that although activated plasminogen activator inhibitor-1 was associated with definite NASH, its association with hepatocyte ballooning was not retained after multivariable adjustment [39]. In addition, a recent model-based study demonstrated that noninvasive biomarkers differ in their ability to reflect individual histological subscores, including steatosis, inflammation, and ballooning [40]. It suggested that PRL may contribute to the severity of MASLD primarily through metabolic-inflammatory activity rather than hepatocellular injury. Remarkably, mediation analysis revealed that PRL influences NAFLD activity score, steatosis score and lobular inflammation score via HOMA-IR. Insulin resistance is a major cause of MASH [41]. It increases the flux of fatty acids from adipose tissue to liver and enhances hepatic triglyceride synthesis, thereby promoting the progression of MASLD [7]. A hyperinsulinemic-euglycemic clamp study showed that PRL deficiency exacerbates insulin resistance [42]. Mechanistically, previous studies have shown that PRL can increase insulin secretion by promoting β- cell proliferation and inhibiting β- cell apoptosis [43, 44]. Further studies are needed to elucidate the mechanisms linking PRL and the histological features of MASLD. No association was observed between serum PRL levels and fibrosis score. Given that fibrosis usually takes a long time to develop, this could be because the participants were quite young in our study [45]. Therefore, future studies examining the impact of PRL on advanced liver fibrosis may need to include older individuals. In our study, the diagnosis of MASLD was determined by the gold standard method with a large sample size of 742 individuals. Nevertheless, several limitations should be acknowledged. First, this is a retrospective study, we are unable to determine a direct cause-and-effect link between PRL levels and MASH. More studies were necessary to validate our findings. Second, the study population consisted predominantly of relatively young individuals with severe obesity and fewer men, which may limit the generalizability of the results to broader populations. Finally, PRL is secreted in a pulsatile manner and is influenced by multiple physiological and environmental factors. Although PRL levels were measured at 8:00 a.m. in all participants to reduce circadian variation, future studies should account for additional factors, including reproductive status, menstrual cycle, and stress. To summarize, this study has for the first time established a potential connection between PRL levels and the histological severity of MASLD. Further, our research discovered that PRL contributed to both liver lipid metabolism and liver inflammation. It may be beneficial to closely monitor individuals with low PRL levels for signs of MASLD or MASH. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1